Bacterial Infection Clinical Trial
Official title:
A Phase 1 Safety and Intrapulmonary Pharmacokinetics Study of ZTI-01 (Intravenous Fosfomycin Disodium) in Healthy Adult Subjects
This is a Phase 1, open-label, multiple-dose trial conducted at a single center. The treatment period will consist of three 6 g doses (18 g) of ZTI-01 as a 1-hour intravenous (IV) infusion (+10 minute window). A total of 30 enrolled subjects will be randomized to undergo a single standardized bronchoscopy with bronchoalveolar lavage (BAL) at one of five sampling times. A total of 6 subjects will be assigned to each BAL-sampling time. Up to ten additional enrolled subjects will act as alternates to obtain 30 evaluable subjects. An evaluable subject is defined as a subject who receives all doses of ZTI-01, undergoes BAL at the randomized sampling timepoint with BAL return volume adequate for testing, and undergoes at least the one blood sampling timepoint that is concurrent with the assigned BAL sampling timepoint, with blood sampling volume that is adequate for testing. The objectives of the study are to assess safety and pharmacokinetics (PK) for a multiple dose regimen of IV-infused ZTI-01.
This is a Phase 1, open-label, multiple-dose trial conducted at a single center. The treatment period will consist of three 6 g doses (18 g) of ZTI-01 as a 1-hour intravenous (IV) infusion (+10 minute window). A total of 30 enrolled subjects will be randomized to undergo a single standardized bronchoscopy with bronchoalveolar lavage (BAL) at one of five sampling times. A total of 6 subjects will be assigned to each BAL-sampling time. Up to ten additional enrolled subjects will act as alternates to obtain 30 evaluable subjects. An evaluable subject is defined as a subject who receives all doses of ZTI-01, undergoes BAL at the randomized sampling timepoint with BAL return volume adequate for testing, and undergoes at least the one blood sampling timepoint that is concurrent with the assigned BAL sampling timepoint, with blood sampling volume that is adequate for testing. The objectives of the study are to assess safety and pharmacokinetics (PK) for a multiple dose regimen of IV-infused ZTI-01. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02794831 -
Exposure to NSAIDs (Non Steroidal Anti-Inflammatory Drugs) and Severity of Community-acquired Bacterial Infections
|
||
Active, not recruiting |
NCT02533609 -
Elimination of Antibiotics During Citrate-anticoagulated Continuous-veno-venous-haemodialysis
|
||
Completed |
NCT01892358 -
Preventing Bacterial and Viral Infections Among Injection Drug Users
|
N/A | |
Completed |
NCT01446289 -
Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings
|
Phase 2 | |
Completed |
NCT01371656 -
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
|
Phase 3 | |
Completed |
NCT01059890 -
Cerebral Antibiotics Distribution After Acute Brain Injury
|
Phase 1 | |
Completed |
NCT00389558 -
Antiseptic Use and Dressing Application
|
Phase 4 | |
Completed |
NCT00760279 -
An Open Label Evaluation of the Pharmacokinetics and Safety of Single Dose Intravenous Azithromycin in Preterm Neonates
|
Phase 1 | |
Completed |
NCT02311816 -
Increase in Procalcitonin Kinetics May be a Good Indicator of Starting Empirical Antibiotic Treatment in Critically Ill Patients
|
N/A | |
Completed |
NCT01225042 -
The Effect of Probiotics on E. Coli Gastroenteritis
|
N/A | |
Completed |
NCT00800488 -
Procalcitonin for Predicting Serious Bacterial Infection in Infants Less Than 3 Months
|
N/A | |
Completed |
NCT00915213 -
Incidence of Antibiotic Resistant E.Coli in Patients Undergoing Repeat Prostate Biopsy
|
N/A | |
Not yet recruiting |
NCT00765778 -
Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community
|
N/A | |
Terminated |
NCT00307099 -
Comparative Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the ICU
|
Phase 3 | |
Recruiting |
NCT04479657 -
Qingfei Granule for the Treatment of the Pediatric Acute Upper Respiratory Tract Infection With Bacterial Infection
|
Early Phase 1 | |
Completed |
NCT03299894 -
Impact of qSOFA Calculation on the Timing of Antimicrobial Therapy in the Emergency Department
|
N/A | |
Completed |
NCT01817075 -
Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
|
Phase 3 | |
Completed |
NCT01250574 -
Neutrophil CD64 and Procalcitonin as Novel Biomarkers for Postoperative Infections
|
||
Completed |
NCT01244698 -
Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction
|
Phase 4 | |
Completed |
NCT01012089 -
Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease
|
N/A |